humanitarian
EMA recommends authorisation of Rasonque for metastatic pancreatic cancer
EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for Rasonque (daraxonrasib), an oral treatment for adults with…
Reported by EMA News and Press Releases
Read the complete report at EMA News and Press Releases ↗
Verification notice
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
3 reports · 3 sources
EMA News and Press ReleasesEMA recommends authorisation of Rasonque for metastatic pancreatic cancerEMA What Is NewEMA recommends authorisation of Rasonque for metastatic pancreatic cancerEMA What Is NewEMA recommends authorisation of Rasonque for metastatic pancreatic cancer4 recorded states
Signal first indexedP2 · 88% quality · 1 source
Corroboration 1→2 sources · quality 88→92P2 · 92% quality · 2 sources
Quality 92→99P2 · 99% quality · 2 sources
Corroboration 2→3 sourcesP2 · 99% quality · 3 sources